Evidence map›Paper›PMID 40806655›Full record

ReviewInternational journal of molecular sciences2025

Angiotensin II and Atherosclerosis: A New Cardiovascular Risk Factor Beyond Hypertension.

Nicola Morat, Giovanni Civieri, Matteo Spezia, Mirko Menegolo, Giacomo Bernava, Sabino Iliceto, Laura Iop, Francesco Tona

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Nicola MoratCardiology Division, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, 35128 Padua, Italy.
Giovanni CivieriCardiology Division, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, 35128 Padua, Italy.ORCID 0000-0002-3076-4787
Matteo SpeziaVascular Surgery Division, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, 35128 Padua, Italy.ORCID 0000-0001-5804-5584
Mirko MenegoloVascular Surgery Division, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, 35128 Padua, Italy.
Giacomo BernavaTranslational Biomedicine Group, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, 35128 Padua, Italy.
Sabino IlicetoSchool of Health, LUM-Libera Università Mediterranea "Giuseppe Degennaro", 70010 Bari, Italy.
Laura IopTranslational Biomedicine Group, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, 35128 Padua, Italy.ORCID 0000-0002-7034-9414
Francesco TonaCardiology Division, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, 35128 Padua, Italy.ORCID 0000-0003-4828-7875

Funding

Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua prot. BIRD202539 - project code U-Gov_BIRD2020_01.
6 · The paper itself

Abstract

The pivotal role of angiotensin II (AngII) in cardiovascular disease has been firmly established, as evidenced by a robust body of literature and the broad clinical application of AngII-inhibiting therapies. AngII type 1 receptor is the primary mediator of AngII action, and its activation initiates a multitude of cellular responses that contribute to the development of hypertension, structural changes in the heart and vasculature, and damage to target organs. This review examines AngII from a different perspective, exploring the link between the renin-angiotensin-aldosterone system and cardiovascular risk beyond hypertension, with particular emphasis on atherosclerosis development and progression.

Indexed as

Angiotensin IIAtherosclerosisCardiovascular DiseasesHypertensionAnimalsHumansReceptor, Angiotensin, Type 1Renin-Angiotensin SystemRisk FactorsAngiotensin IIReceptor, Angiotensin, Type 1angiotensinatherosclerosishypertensioninflammationplaque instabilityRAASrisk factor

Identifiers

PMID40806655
PMCPMC12347662

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.